Kyverna’s CAR-T data clears the durability bar, but tiny gMG cohort remains

Kyverna is a late-stage clinical immunology company trying to move miv-cel from promising autoimmune CAR-T data toward an SPS approval while running a pivotal gMG trial. The broad direction was already established: the company had initiated the rolling SPS BLA, expected these longer-term data in the third quarter, and guided to gMG Phase 3 enrollment completion in mid-2027.

SPS durability is the clearest upgrade. In the 26-patient registrational trial, the key walking improvement did not fade at one year: median T25FW improvement was 49% at month 12 versus 46% at week 16, and 95% of patients who achieved a clinically meaningful response sustained it. 〔0〕 That is more than a repeat of the initial endpoint win; it directly supports Kyverna’s central commercial and regulatory argument that one infusion may replace chronic disease management. The fact that 92% remained free of chronic SPS immunotherapies adds practical weight. 〔1〕

The safety profile remains unusually clean for a CAR-T program, but this is confirmation rather than a new surprise. No high-grade CRS, ICANS, or IEC-HS appeared through the one-year follow-up. 〔2〕 That matters because tolerability is central to making an autologous CAR-T treatment viable in autoimmune disease, but Kyverna had already emphasized the same safety pattern across more than 100 treated patients in its recent pre-filing update.

gMG data are directionally strong but still preliminary. All seven Phase 2 patients achieved clinically meaningful MG-ADL and QMG improvement at 24 weeks, while follow-up now reaches one year or longer in five patients. 〔3〕 Six of seven remained off immunosuppressants at last follow-up, and 57% maintained minimal symptom expression. Those results reinforce the earlier positive signal, but the sample is too small and single-arm to establish comparative efficacy; the roughly 60-patient randomized Phase 3 trial remains the real validation step. The company still expects that enrollment to finish in mid-2027. 〔4〕

Bottom line: This is a meaningful de-risking update, especially for the SPS BLA: benefit persists, patients remain off chronic therapy, and no new safety problem emerges. It strengthens the approval story, while gMG remains a promising but still small-cohort thesis awaiting randomized Phase 3 confirmation.